Tygacil Drug Use Investigation
Information source: Pfizer
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Intra-Abdominal Infections; Skin Disease, Infectious
Intervention: Tigecycline (Tygacil) (Drug)
Phase: N/A
Status: Active, not recruiting
Sponsored by: Pfizer Official(s) and/or principal investigator(s):
Pfizer CT.gov Call Center, Study Director, Affiliation: Pfizer
Summary
To collect retrospectively the effectiveness and safety information of tigecycline related
to their appropriate use in daily practice.
Clinical Details
Official title: Tygacil Drug Use Investigation (Tigecycline Evaluation Study For Safety And Effectiveness In Patient Infected With Multi-drug Resistance.)
Study design: Observational Model: Case-Only, Time Perspective: Retrospective
Primary outcome: Number of Participants with Clinical Response of Cure at the Test-of-Cure (TOC) Visit
Eligibility
Minimum age: N/A.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- All patients who are prescribed tigecycline (Tygacil).
Exclusion Criteria:
- Subject who have been prescribed tigecycline (Tygacil).
Locations and Contacts
Additional Information
To obtain contact information for a study center near you, click here.
Starting date: April 2013
Last updated: July 29, 2015
|
